BCR and B-cell chronic lymphocytic leukemia: CLL progression largely relies on intense B-cell receptor (BCR) signaling, and small molecule inhibitors have successfully been used to target the BCR pathway, notably Ibrutinib, which inhibits Bruton tyrosine kinase (BTK) [13].